Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
Main finding · AFResult — go to the resultAdjusted hazard ratio 0.77 95% CI 0.68–0.88Authors' conclusion
SGLT-2is were associated with a reduced risk of AF in patients with type 2 diabetes compared to other second-line to third-line antidiabetic drugs. This reduced risk occurs in both sexes but more prominently among women.
Study context
- Population
- Patients with T2DM initiating a new antidiabetic drug class, UK Clinical Practice Research Datalink, January 2013–September 2020, without prior atrial fibrillation (AF) or atrial flutter
- Participants
- 142,447 patients
- Exposure
- SGLT2 inhibitors vs other second-line to third-line antidiabetic drugs
- Outcome
- AF
Methodological detailsnew-user active comparator
- New-user active comparator
Main finding
As reported in the abstract
Adjusted hazard ratio
0.77
95% CI 0.68–0.88
SGLT-2is vs Other second-line to third-line antidiabetic drugs
adjusted HR 0.77 (95% CI 0.68–0.88)
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| AF, by sex (subgroup)SGLT-2is vs Other second-line to third-line antidiabetic drugs · women | 0.60 (0.45–0.79) | |
| AF, by sex (subgroup)SGLT-2is vs Other second-line to third-line antidiabetic drugs · men | 0.85 (0.73–0.98) | |
| 0.512Adjusted hazard ratio (log scale) |
- AF, by sex (subgroup): interaction P: 0.012
AF, by diabetes duration, body mass index (BMI), HbA1c, HF (subgroups)
- No evidence for effect modification by diabetes duration, BMI, HbA1c or HF
Original publication
Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. Eur Heart J Cardiovasc Pharmacother. Published 22 March 2024. doi:10.
Summarised from the published abstract; every number is checked against it